KRYSTAL-12: Phase 3 Study of MRTX849 vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation
KRYSTAL 849-012: A Randomized Phase 3 Study of MRTX849 versus Docetaxel in Patients with Previously Treated Non-Small Cell Lung Cancer with KRAS G12C Mutation
-
Clinical Trial Information
Trial Contact: Thomas, Andrea L
Trial Phone: 321.841.8284
-
IRB No: S21.015.01
Protocol Abbrev: KRYSTAL 849-012
Principal Investigator: Tirrell Tremayne Johnson, MD
Phase: Drug: Phase III
Age Group: Adult
Secondary Protocol No: KRYSTAL 849-012
Treatment: Investigational agent MRTX849 or Docetaxel
Therapies Involved: Chemotherapy
ClinicalTrials.gov ID: NCT04685135
-
Objective
To compare the efficacy of MRTX849 versus docetaxel in patients with NSCLC with KRAS G12C mutation and who have received prior treatment with a platinum-based regimen and immune checkpoint inhibitor therapy.
-
Key Eligibility
-Histologically or cytologically confirmed diagnosis of NSCLC with KRAS G12C mutation.
-Candidacy to receive treatment with docetaxel.
-18 years and older
